At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 23, 2026 at 16:07 ET
Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratification of Ilan Ganot's board appointment, a share increase to 480 million, and advisory votes on executive compensation. This follows a recent board reshuffle where Ganot was reappointed to a different class, indicating ongoing governance adjustments.
- Election of Class II directors Clare Kahn, Adam Stone, and Lynne Sullivan
- Ratification of Ilan Ganot's appointment to Class I director
- Ratification of PricewaterhouseCoopers as independent auditor
- Proposal to increase authorized shares from 240M to 480M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access